Acutus Medical (NASDAQ:AFIB) & InspireMD (NYSE:NSPR) Head-To-Head Review

Acutus Medical (NASDAQ:AFIB) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Acutus Medical and InspireMD, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acutus Medical	0	0	0	0	0.00
InspireMD	0	0	2	0	3.00

InspireMD has a consensus target price of $4.50, indicating a potential upside of 129.59%. Given InspireMD’s stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Acutus Medical.

Institutional and Insider Ownership

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by company insiders. Comparatively, 29.7% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Acutus Medical and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acutus Medical	-272.74%	-311.64%	-11.57%
InspireMD	-413.96%	-69.42%	-57.68%

Risk and Volatility

Acutus Medical has a beta of -0.75, indicating that its stock price is 175% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Valuation & Earnings

This table compares Acutus Medical and InspireMD”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acutus Medical	$7.16 million	0.00	-$81.66 million	($0.11)	0.00
InspireMD	$7.07 million	11.57	-$19.92 million	($0.83)	-2.36

InspireMD has lower revenue, but higher earnings than Acutus Medical. InspireMD is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.

Summary

InspireMD beats Acutus Medical on 8 of the 14 factors compared between the two stocks.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.